NRC Correction to Its FY 2026 Medical License Fees Repeats the Same Dollar Amounts

ANALYSIS · October 19, 2026

Slug: fee-schedules-fee-recovery-fiscal-year-2026

Package note: This Analysis covers a Nuclear Regulatory Commission correction published in the Federal Register on October 19, 2026 (91 FR 65941, FR Doc. C1-2026-12067, docket NRC-2023-0212). It amends entry 7.C in Table 2 to paragraph (d) of 10 CFR 171.16, the annual-fee table, in the NRC’s FY 2026 fee rule. That rule was published June 16, 2026, at 91 FR 36470–36509 and took effect August 17, 2026. We compared the correction line by line with the June rule text on federalregister.gov.

Primary sources

• Federal Register, “Fee Schedules; Fee Recovery for Fiscal Year 2026,” correction (October 19, 2026), 91 FR 65941: https://www.federalregister.gov/documents/2026/10/19/C1-2026-12067/fee-schedules-fee-recovery-for-fiscal-year-2026
• Federal Register, “Fee Schedules; Fee Recovery for Fiscal Year 2026,” final rule (June 16, 2026), 91 FR 36470: https://www.federalregister.gov/documents/2026/06/16/2026-12067/fee-schedules-fee-recovery-for-fiscal-year-2026

Category 7.C covers “other licenses issued under parts 30, 35, 40, and 70” for human use of byproduct, source or special nuclear material. That excludes sealed sources in teletherapy devices. In practice it covers most medical-use materials licenses, priced by number of locations of use. The correction reprints all three tiers of 7.C. It lists $23,300 for 1–5 locations and $33,000 for 6–20 locations. For more than 20 locations, the correction prints the category text and program codes but no dollar amount. The June rule sets that tier at $42,300.

Core Tension

The correction doesn’t change any fee. The $23,300 and $33,000 figures are the same ones the June rule already set for these tiers. The only difference we found between the two texts is in the 1–5 location tier: the correction adds footnote 19 to it, matching the other two tiers. Footnote 19 says licensees paying broad-scope medical fees under 7.B, 7.B.1 or 7.B.2 “are not subject to paying fees under 7.C., 7.C.1, or 7.C.2” for human-use licenses authorized on the same license. That makes the double-billing exemption apply to the smallest tier as well. The notice doesn’t say what the error was. Its page citation is also wrong: it points to “pages 6504 and 6505” of a rule that runs from page 36470 to 36509. In the June rule, entry 7.C appears on pages 36507–36508.

The full Analysis comes with membership: what the document does, the claims check, and what to watch. Become a member or sign in. Founding members (first 100): $30 the first year, then $50/yr.